Does the media favor ASMB or PLYX?

In the previous week, Polaryx Therapeutics had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 6 mentions for Polaryx Therapeutics and 5 mentions for Assembly Biosciences. Polaryx Therapeutics' average media sentiment score of 1.21 beat Assembly Biosciences' score of 0.58 indicating that Polaryx Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Polaryx Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CGC or PLYX?

Polaryx Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 194.87%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Polaryx Therapeutics is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Does the media refer more to CGC or PLYX?

In the previous week, Canopy Growth had 7 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 13 mentions for Canopy Growth and 6 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.21 beat Canopy Growth's score of 1.11 indicating that Polaryx Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 7 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Polaryx Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, AVIR or PLYX?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A Polaryx Therapeutics N/A N/A -$8.98M -$0.05 N/A

Is AVIR or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -64.25% -57.12% Polaryx Therapeutics N/A N/A N/A

Does the media prefer AVIR or PLYX?

In the previous week, Atea Pharmaceuticals and Atea Pharmaceuticals both had 6 articles in the media. Polaryx Therapeutics' average media sentiment score of 1.21 beat Atea Pharmaceuticals' score of 1.18 indicating that Polaryx Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Polaryx Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ENTA or PLYX?

In the previous week, Enanta Pharmaceuticals had 7 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 13 mentions for Enanta Pharmaceuticals and 6 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.21 beat Enanta Pharmaceuticals' score of -0.44 indicating that Polaryx Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Polaryx Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PLYX or FENC?

In the previous week, Adherex Technologies had 4 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 10 mentions for Adherex Technologies and 6 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.21 beat Adherex Technologies' score of 0.67 indicating that Polaryx Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polaryx Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adherex Technologies 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Polaryx Therapeutics (PLYX) Competitors

$2.60 +0.10 (+4.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.55 -0.05 (-1.92%)

As of 07:34 PM Eastern

Compare

PLYX vs. ASMB, CGC, AVIR, ENTA, and FENC

Should you buy Polaryx Therapeutics stock or one of its competitors? Polaryx Therapeutics's main competitors and comparable companies include Assembly Biosciences (ASMB), Canopy Growth (CGC), Atea Pharmaceuticals (AVIR), Enanta Pharmaceuticals (ENTA), and Adherex Technologies (FENC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Polaryx Therapeutics compare to Assembly Biosciences?

Assembly Biosciences (NASDAQ:ASMB) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

Assembly Biosciences has higher revenue and earnings than Polaryx Therapeutics. Assembly Biosciences is trading at a lower price-to-earnings ratio than Polaryx Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$72.30M	7.24	-$6.12M	-$0.11	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.05	N/A

Assembly Biosciences currently has a consensus target price of $44.00, indicating a potential upside of 33.54%. Polaryx Therapeutics has a consensus target price of $7.67, indicating a potential upside of 194.87%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

19.9% of Assembly Biosciences shares are held by institutional investors. 3.5% of Assembly Biosciences shares are held by company insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Polaryx Therapeutics had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 6 mentions for Polaryx Therapeutics and 5 mentions for Assembly Biosciences. Polaryx Therapeutics' average media sentiment score of 1.21 beat Assembly Biosciences' score of 0.58 indicating that Polaryx Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Polaryx Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Polaryx Therapeutics has a net margin of 0.00% compared to Assembly Biosciences' net margin of -0.06%. Polaryx Therapeutics' return on equity of 0.00% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-0.06%	-0.02%	-0.02%
Polaryx Therapeutics	N/A	N/A	N/A

Summary

Polaryx Therapeutics beats Assembly Biosciences on 10 of the 15 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

Polaryx Therapeutics has lower revenue, but higher earnings than Canopy Growth. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$251.01M	1.82	-$190.29M	-$0.45	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.05	N/A

In the previous week, Canopy Growth had 7 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 13 mentions for Canopy Growth and 6 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.21 beat Canopy Growth's score of 1.11 indicating that Polaryx Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	7 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Polaryx Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.3% of Canopy Growth shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Polaryx Therapeutics has a consensus price target of $7.67, suggesting a potential upside of 194.87%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Polaryx Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Polaryx Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Polaryx Therapeutics' return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-65.33%	-21.91%	-14.34%
Polaryx Therapeutics	N/A	N/A	N/A

Summary

Polaryx Therapeutics beats Canopy Growth on 10 of the 14 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.05	N/A

Polaryx Therapeutics' return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
Polaryx Therapeutics	N/A	N/A	N/A

In the previous week, Atea Pharmaceuticals and Atea Pharmaceuticals both had 6 articles in the media. Polaryx Therapeutics' average media sentiment score of 1.21 beat Atea Pharmaceuticals' score of 1.18 indicating that Polaryx Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polaryx Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Atea Pharmaceuticals presently has a consensus target price of $7.00, suggesting a potential upside of 36.72%. Polaryx Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 194.87%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Polaryx Therapeutics beats Atea Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

Polaryx Therapeutics has lower revenue, but higher earnings than Enanta Pharmaceuticals. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.87	-$81.89M	-$2.41	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.05	N/A

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Polaryx Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. Polaryx Therapeutics' return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Polaryx Therapeutics	N/A	N/A	N/A

In the previous week, Enanta Pharmaceuticals had 7 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 13 mentions for Enanta Pharmaceuticals and 6 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.21 beat Enanta Pharmaceuticals' score of -0.44 indicating that Polaryx Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Polaryx Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enanta Pharmaceuticals presently has a consensus target price of $19.50, indicating a potential upside of 48.18%. Polaryx Therapeutics has a consensus target price of $7.67, indicating a potential upside of 194.87%. Given Polaryx Therapeutics' higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Polaryx Therapeutics beats Enanta Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Adherex Technologies?

Polaryx Therapeutics (NASDAQ:PLYX) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

55.5% of Adherex Technologies shares are owned by institutional investors. 45.8% of Polaryx Therapeutics shares are owned by insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Polaryx Therapeutics currently has a consensus target price of $7.67, suggesting a potential upside of 194.87%. Adherex Technologies has a consensus target price of $16.40, suggesting a potential upside of 39.93%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Polaryx Therapeutics is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Polaryx Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Polaryx Therapeutics' return on equity of 0.00% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Adherex Technologies	-6.09%	-6.93%	-2.48%

In the previous week, Adherex Technologies had 4 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 10 mentions for Adherex Technologies and 6 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.21 beat Adherex Technologies' score of 0.67 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polaryx Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adherex Technologies	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Polaryx Therapeutics has higher earnings, but lower revenue than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Polaryx Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.05	N/A
Adherex Technologies	$44.64M	9.20	-$9.74M	-$0.13	N/A

Summary

Polaryx Therapeutics beats Adherex Technologies on 11 of the 15 factors compared between the two stocks.

Get Polaryx Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLYX vs. The Competition

Export

Metric	Polaryx Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$124.61M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-52.00	775.15	269.06	25.28
Price / Sales	N/A	743.86	602.43	91.76
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	26.00	11.60	12.91	6.24
Net Income	-$8.98M	$2.77B	$3.45B	$347.60M
7 Day Performance	15.04%	0.17%	1.12%	1.07%
1 Month Performance	15.04%	0.35%	1.79%	1.03%
1 Year Performance	N/A	161.52%	67.69%	20.77%

Polaryx Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLYX Polaryx Therapeutics	4.4887 of 5 stars	$2.60 +4.0%	$7.67 +194.9%	N/A	$124.61M	N/A	N/A	11	News Coverage Positive News Earnings Report Analyst Forecast
ASMB Assembly Biosciences	2.5765 of 5 stars	$26.68 +0.9%	$44.00 +64.9%	+21.0%	$420.36M	$72.30M	N/A	100	News Coverage Earnings Report
CGC Canopy Growth	0.9 of 5 stars	$0.97 +4.1%	N/A	-38.4%	$418.01M	$251.01M	N/A	1,128	Positive News Earnings Report Analyst Downgrade High Trading Volume
AVIR Atea Pharmaceuticals	2.8314 of 5 stars	$5.25 +5.2%	N/A	+44.9%	$399.33M	N/A	N/A	70	Positive News Earnings Report Analyst Forecast
ENTA Enanta Pharmaceuticals	1.5512 of 5 stars	$13.77 +3.2%	$20.29 +47.3%	+77.3%	$387.90M	$69.21M	N/A	160	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLYX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. ASMB, CGC, AVIR, ENTA, and FENC

How does Polaryx Therapeutics compare to Assembly Biosciences?

Summary

How does Polaryx Therapeutics compare to Canopy Growth?

Summary

How does Polaryx Therapeutics compare to Atea Pharmaceuticals?

Summary

How does Polaryx Therapeutics compare to Enanta Pharmaceuticals?

Summary

How does Polaryx Therapeutics compare to Adherex Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. ASMB, CGC, AVIR, ENTA, and FENC

How does Polaryx Therapeutics compare to Assembly Biosciences?

Which has preferable earnings and valuation, ASMB or PLYX?

Do analysts rate ASMB or PLYX?

Do institutionals & insiders hold more shares of ASMB or PLYX?

Does the media favor ASMB or PLYX?

Is ASMB or PLYX more profitable?

Summary

How does Polaryx Therapeutics compare to Canopy Growth?

Which has better earnings & valuation, CGC or PLYX?

Does the media refer more to CGC or PLYX?

Do insiders & institutionals hold more shares of CGC or PLYX?

Do analysts recommend CGC or PLYX?

Is CGC or PLYX more profitable?

Summary

How does Polaryx Therapeutics compare to Atea Pharmaceuticals?

Which has stronger valuation & earnings, AVIR or PLYX?

Is AVIR or PLYX more profitable?

Does the media prefer AVIR or PLYX?

Do insiders & institutionals hold more shares of AVIR or PLYX?

Do analysts rate AVIR or PLYX?

Summary

How does Polaryx Therapeutics compare to Enanta Pharmaceuticals?

Which has preferable valuation and earnings, ENTA or PLYX?

Do insiders and institutionals believe in ENTA or PLYX?

Is ENTA or PLYX more profitable?

Does the media prefer ENTA or PLYX?

Do analysts rate ENTA or PLYX?

Summary

How does Polaryx Therapeutics compare to Adherex Technologies?

Do institutionals & insiders hold more shares of PLYX or FENC?

Do analysts rate PLYX or FENC?

Is PLYX or FENC more profitable?

Does the media favor PLYX or FENC?

Which has better valuation & earnings, PLYX or FENC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools